Vapotherm’s Precision Flow Hi-VNI system, which is clinically proven to treat both Type 1 (hypoxic) and Type II (hypercapnic) respiratory distress, is the only HFNC product listed under the United ...

Respiratory care specialist Vapotherm raised $56 million in an initial public offering of 4 million shares, priced at the low end of the range at $14. The Exeter, New Hampshire-based company plans to ...

Infinium Medical, through its Infinium Veterinary division will be exclusively distributing Vapotherm VET 2.0 high-velocity respiratory therapy systems. This partnership allows us to provide ...

New Hampshire-based medical device maker Vapotherm Inc. says it is expanding its manufacturing capabilities in Exeter as it focuses on developing and commercializing its Hi-VNI technology products ...

EXETER, N.H., Feb. 22, 2024 /PRNewswire/ -- Vapotherm, Inc. (VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2023 financial results and related highlights. Fourth ...

The company's products are getting exposure, thanks in part to the coronavirus pandemic. The Exeter, N.H., medical technology company specializes in products to treat respiratory diseases. Here are ...

Increased capacity anticipated to scale capital production by up to 20X above pre-COVID-19 pandemic levels At maximum capacity, increased production could create up to 350 manufacturing jobs in New ...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® ...

Vapotherm’s Precision Flow Hi-VNI system provides more precise control over the amount of oxygen being delivered to patients than conventional HFNC systems, as the Vapotherm Precision Flow Hi-VNI ...